Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase I Study of DS-8201a in Combination With Olaparib in HER2-Expressing Malignancies

This phase I trial identifies the side effects and best dose of DS-8201a and olaparib in treating patients with HER2-expressing cancers that have spread to oth…

Metastatic Malignant Solid NeoplasmPlatinum-Resistant Ovarian High Grade Serous AdenocarcinomaUnresectable Malignant Solid Neoplasm

National Cancer Institute (NCI)NCT04585958